University of Illinois

Vanquish Oncology, Inc.

The Johns Hopkins University

Timothy M Fan

Paul Joseph Hergenrother

Mark J Gilbert

Rachel C Botham

Michael K Handley

Theodore Michael Tarasow

Gregory J Riggins

Avadhut D Joshi

Howard S Roth

Quinn Patrick Peterson

Danny Chung Hsu

Diana C West

Chris J Novotny

Martin D Burke

Robin L Holland

Christopher B Brooke

Leyi Wang

Kelsie J Green

Fadi G Alnaji

Diana Rose Ranoa

Michael J Handley

Riley L Svec

Theodore M Tarasow

Compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other cancer therapies that achieve the same or similar therapeutic effect.

Procaspase combination therapy for glioblastoma

New synthetic methods to provide access to previously unexplored functionality at the C8 position of substituted imidazo[5,1-d][1,2,3,5]tetrazines of Formula I. Through synthesis and evaluation of a suite of compounds with a range of aqueous stabilities (from 0.5 to 40 hours), a predictive model for imidazotetrazine hydrolytic stability based on the Hammett constant of the C8 substituent was derived. Promising compounds were identified that possess activity against a panel of GBM cell lines, appropriate hydrolytic and metabolic stability, and brain-to-serum ratios dramatically elevated relative to TMZ, leading to lower hematological toxicity profiles and superior activity to TMZ in a mouse model of GBM.

Substituted imidazo[5,1-d][1,2,3,5]tetrazines for the treatment of cancer

A saliva-based testing method that bypasses the need for RNA isolation/purification is described herein. In experiments with inactivated SARS-CoV-2 virus spiked into saliva, this method has a limit of detection of 500-1000 viral particles per mL, rivalling the standard NP swab method. Initial studies showed excellent performance with 100 clinical samples. This saliva-based process is operationally simple, utilizes readily available materials, and can be easily implemented by existing testing sites thus allowing for high-throughput, rapid, and repeat testing of large populations.

Saliva-based molecular testing for SARS-CoV-2

The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.

Procaspase 3 activation by combination therapy

Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.

Procaspase activating compounds

The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods the use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.

Potent anticancer activity via dual compound activation

Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs

Growing community of inventors

Mahomet, IL, United States of America

Timothy M Fan